Stacey Ehrenberg, MD, discusses the lacking data and potential implications of using glucagon-like peptide-1 (GLP-1) receptor agonists during pregnancy for patients with diabetes and/or obesity.
Stacey Ehrenberg, MD, a maternal fetal medicine specialist at Cleveland Clinic, presented at a recent Institute for Value-Based Medicine® event on the optimal approach to diabetes and obesity for patients who are pregnant. In a virtual interview, Ehrenberg discussed in greater detail the special considerations both patients and clinicians should be aware of in the use of glucagon-like peptide-1 (GLP-1) receptor agonists during pregnancy.
Transcript
This transcript has been lightly edited for clarity and length.
Are there any particular factors clinicians or patients should be aware of when considering GLP-1 receptor agonist therapy during pregnancy?
So using the GLP-1 agonists has been a huge topic of conversation, both in the medical field and in the general population. And so, we're getting a lot of questions about, “Can we use this in pregnancy?” We're hearing a lot about, you know, Ozempic babies or Mounjaro babies and people are like, “What does that mean?” And you know, “Is that safe? Can we do that?” And these medications are fantastic in trying to optimize a patient's hemoglobin A1c, or their average blood sugars and their weight prior to pregnancy, or just in the general population.
In pregnancy, we really don't have a lot of data on the long-term effects. We certainly don't have data on the long-term effects of these medications. But we really don't even have a lot of short-term data, either. We've got some case reports, and there was one recent study that was published in JAMA, I believe, in January of 2024 of this year, looking at these medications in early pregnancy. And so far, we're a little bit hopeful that we may be able to not so much use these medications in the first trimester of pregnancy, but in patients who happened to be on them and didn't realize they were pregnant until 6, 8, 10, 12 weeks—which is common. We're hopeful that the data shows that we don't see any increased risk of birth defects and women who have been on these medications before pregnancy, and maybe even a little bit during the first trimester of pregnancy. It doesn't seem to be a concern for the babies.
What we do know is that later in pregnancy, in the second and third trimester, we have seen some increased risks with the baby's kidneys, with the baby's growth velocity. So I'm not sure that these are going to be medications that we can keep patients on throughout the entire pregnancy. Although, I think we need more data before I would feel very confident in saying that with certainty. But right now, I think it's best not to use them because we just don't have the information. And the information we do have is somewhat concerning. And whether it's the medication itself causing these complications in the babies or whether it's the weight loss and the inability to eat enough calories to support a pregnancy while on these medications is questionable. I can't really say what the mechanism of action is but the end result right now is that we're concerned about patients continuing on these medications into the second and third trimester, because we're worried that it can affect the health and wellbeing of the baby.
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More